• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges.利用 SARS-CoV-2 的基因组学和免疫病理学开发疫苗:前景与挑战。
Hum Vaccin Immunother. 2021 Mar 4;17(3):620-637. doi: 10.1080/21645515.2020.1812313. Epub 2020 Sep 16.
2
SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants.SARS-CoV-2 感染:新的分子、系统发生和发病机制见解。当前疫苗的功效和变异的潜在风险。
Viruses. 2021 Aug 25;13(9):1687. doi: 10.3390/v13091687.
3
SARS-CoV-2 vaccine candidates in rapid development.正在快速开发的 SARS-CoV-2 疫苗候选物。
Hum Vaccin Immunother. 2021 Mar 4;17(3):644-653. doi: 10.1080/21645515.2020.1804777. Epub 2020 Oct 29.
4
New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.用于开发 SARS-CoV-2 候选疫苗的新型疫苗生产平台。
Vaccine. 2021 Jan 8;39(2):197-201. doi: 10.1016/j.vaccine.2020.11.054. Epub 2020 Nov 24.
5
Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.基于 SARS-CoV-2 的免疫原性结构蛋白、宿主免疫反应和群体免疫的 COVID-19 疫苗开发的新见解。
Cells. 2021 Oct 29;10(11):2949. doi: 10.3390/cells10112949.
6
On the road to ending the COVID-19 pandemic: Are we there yet?走向终结新冠大流行之路:我们是否已经到达终点?
Virology. 2021 May;557:70-85. doi: 10.1016/j.virol.2021.02.003. Epub 2021 Feb 26.
7
Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update.SARS-CoV-2/COVID-19 大流行管理的潜在治疗靶点和疫苗开发:近期进展综述。
Front Immunol. 2021 Jun 30;12:658519. doi: 10.3389/fimmu.2021.658519. eCollection 2021.
8
Quantitative Insight into Immunopathology of SARS-CoV-2 Infection.对SARS-CoV-2感染免疫病理学的定量洞察。
J Interferon Cytokine Res. 2021 Jul;41(7):244-257. doi: 10.1089/jir.2020.0156.
9
SARS-CoV-2 Variants, Vaccines, and Host Immunity.SARS-CoV-2 变体、疫苗和宿主免疫。
Front Immunol. 2022 Jan 3;12:809244. doi: 10.3389/fimmu.2021.809244. eCollection 2021.
10
Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines.新冠病毒变异株对新冠疫情紧急使用疫苗的免疫逃逸作用
Front Immunol. 2021 Nov 22;12:771242. doi: 10.3389/fimmu.2021.771242. eCollection 2021.

引用本文的文献

1
A hybrid approach based on ELECTRE III-genetic algorithm and TOPSIS method for selection of optimal COVID-19 vaccines.一种基于ELECTRE III-遗传算法和TOPSIS方法的混合方法用于选择最佳的新冠疫苗。
J Multi Criteria Decis Anal. 2022 Jan-Apr;29(1-2):80-91. doi: 10.1002/mcda.1772. Epub 2021 Nov 15.
2
Antibody-Based Immunotherapeutic Strategies for COVID-19.针对新型冠状病毒肺炎的基于抗体的免疫治疗策略
Pathogens. 2020 Nov 5;9(11):917. doi: 10.3390/pathogens9110917.

本文引用的文献

1
On the origin and continuing evolution of SARS-CoV-2.关于严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的起源及持续进化
Natl Sci Rev. 2020 Jun;7(6):1012-1023. doi: 10.1093/nsr/nwaa036. Epub 2020 Mar 3.
2
Novel coronavirus 2019-nCoV (COVID-19): early estimation of epidemiological parameters and epidemic size estimates.新型冠状病毒 2019-nCoV (COVID-19):流行病学参数和疫情规模的早期估计。
Philos Trans R Soc Lond B Biol Sci. 2021 Jul 19;376(1829):20200265. doi: 10.1098/rstb.2020.0265. Epub 2021 May 31.
3
Comparative ACE2 variation and primate COVID-19 risk.比较 ACE2 变异与灵长类动物 COVID-19 风险。
Commun Biol. 2020 Oct 27;3(1):641. doi: 10.1038/s42003-020-01370-w.
4
Genomic Diversity and Hotspot Mutations in 30,983 SARS-CoV-2 Genomes: Moving Toward a Universal Vaccine for the "Confined Virus"?30983个新冠病毒基因组中的基因组多样性与热点突变:朝着研发针对“受限病毒”的通用疫苗迈进?
Pathogens. 2020 Oct 10;9(10):829. doi: 10.3390/pathogens9100829.
5
Implications of SARS-CoV-2 genetic diversity and mutations on pathogenicity of the COVID-19 and biomedical interventions.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的基因多样性和突变对2019冠状病毒病(COVID-19)致病性及生物医学干预措施的影响
J Taibah Univ Med Sci. 2020 Aug;15(4):258-264. doi: 10.1016/j.jtumed.2020.06.005. Epub 2020 Jul 10.
6
Africa's struggle with inadequate COVID-19 testing.非洲在新冠病毒检测不足方面面临的困境。
Lancet Microbe. 2020 May;1(1):e12. doi: 10.1016/S2666-5247(20)30014-8. Epub 2020 May 11.
7
Assessment of the SARS-CoV-2 basic reproduction number, , based on the early phase of COVID-19 outbreak in Italy.基于意大利新冠疫情早期阶段对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)基本繁殖数\(R_0\)的评估。
Biosaf Health. 2020 Jun;2(2):57-59. doi: 10.1016/j.bsheal.2020.03.004. Epub 2020 Apr 2.
8
Developing a low-cost and accessible COVID-19 vaccine for global health.为全球健康研发一种低成本且易于获取的新冠疫苗。
PLoS Negl Trop Dis. 2020 Jul 29;14(7):e0008548. doi: 10.1371/journal.pntd.0008548. eCollection 2020 Jul.
9
Emerging manufacturers engagements in the COVID -19 vaccine research, development and supply.新兴制造商在 COVID-19 疫苗研究、开发和供应中的参与。
Vaccine. 2020 Jul 22;38(34):5418-5423. doi: 10.1016/j.vaccine.2020.06.022. Epub 2020 Jun 11.
10
Current global vaccine and drug efforts against COVID-19: Pros and cons of bypassing animal trials.当前全球针对 COVID-19 的疫苗和药物研发:绕过动物试验的利弊。
J Biosci. 2020;45(1). doi: 10.1007/s12038-020-00053-2.

利用 SARS-CoV-2 的基因组学和免疫病理学开发疫苗:前景与挑战。

Leveraging on the genomics and immunopathology of SARS-CoV-2 for vaccines development: prospects and challenges.

机构信息

Department of Medical Laboratory Science, Faculty of Allied Health Sciences, College of Medical Sciences, Ahmadu Bello University, Zaria, Nigeria.

Department of Medical Laboratory Science, Faculty of Allied Medical Sciences, University of Calabar, Calabar, Nigeria.

出版信息

Hum Vaccin Immunother. 2021 Mar 4;17(3):620-637. doi: 10.1080/21645515.2020.1812313. Epub 2020 Sep 16.

DOI:10.1080/21645515.2020.1812313
PMID:
32936732
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7993231/
Abstract

The incidence and case-fatality rates (CFRs) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, the etiological agent for Coronavirus Disease 2019 (COVID-19), have been rising unabated. Even though the entire world has been implementing infection prevention and control measures, the pandemic continues to spread. It has been widely accepted that preventive vaccination strategies are the public health measures for countering this pandemic. This study critically reviews the latest scientific advancement in genomics, replication pattern, pathogenesis, and immunopathology of SARS-CoV-2 infection and how these concepts could be used in the development of vaccines. We also offer a detailed discussion on the anticipated potency, efficacy, safety, and pharmaco-economic issues that are and will be associated with candidate COVID-19 vaccines.

摘要

严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)感染的发病率和病死率(CFR)持续上升,SARS-CoV-2 是导致 2019 年冠状病毒病(COVID-19)的病原体。尽管全世界一直在实施感染预防和控制措施,但大流行仍在继续蔓延。人们普遍认为,预防接种策略是应对这一大流行病的公共卫生措施。本研究批判性地回顾了 SARS-CoV-2 感染的基因组学、复制模式、发病机制和免疫病理学的最新科学进展,以及这些概念如何用于疫苗的开发。我们还详细讨论了与候选 COVID-19 疫苗相关的预期效力、功效、安全性和药物经济学问题,以及这些问题现在和将来会如何出现。